Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Cancer Treat Rev. 2011 Feb;37(1):63-74. doi: 10.1016/j.ctrv.2010.05.001. Epub 2010 Jun 8.

The unique characteristics of tumor vasculature and preclinical evidence for its selective disruption by Tumor-Vascular Disrupting Agents.

Author information

  • Department of Radiation Oncology, University of Florida College of Medicine, Gainesville, FL, USA. siemadw@ufl.edu

Abstract

The vasculature of solid tumors is fundamentally different from that of normal vasculature and offers a unique target for anti-cancer therapy. Direct vascular-targeting with Tumor-Vascular Disrupting Agents (Tumor-VDAs) is distinctly different from anti-angiogenic strategies, and offers a complementary approach to standard therapies. Tumor-VDAs therefore have significant potential when combined with chemotherapy, radiotherapy, and angiogenesis-inhibiting agents. Preclinical studies with the different Tumor-VDA classes have demonstrated key tumor-selective anti-vascular and anti-tumor effects.

Copyright © 2010 Elsevier Ltd. All rights reserved.

PMID:
20570444
[PubMed - indexed for MEDLINE]
PMCID:
PMC2958232
Free PMC Article

Images from this publication.See all images (13)Free text

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
Figure 7
Figure 8
Figure 9
Figure 10
Figure 11
Figure 12
Figure 13
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science Icon for PubMed Central
    Loading ...
    Write to the Help Desk